Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. This new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. The aim is to provide potential new therapies for patients with difficult to treat lung and gastrointestinal cancers.
“We are excited to partner with Enara Bio as part of our mission to bring transformative new treatments to cancer patients,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research, Boehringer Ingelheim. “We are advancing a unique pipeline of cancer cell-directed agents, immuno-oncology therapies and intelligent combination approaches to help combat cancer. Enara Bio’s unique discovery platform offers a novel and highly differentiated approach that will allow us to look beyond the known proteome to identify and characterize Dark Antigens to support the development of T-Cell Receptor (TCR)-directed immunotherapies and therapeutic vaccines. We believe this is a highly innovative and promising approach to the development of the next wave of cancer immunotherapies.”
Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT™) will be used to discover and validate novel Dark Antigens in up to three tumor types in the lung and gastrointestinal cancer space. The discovery of shared antigens could lead to the development of vaccines that can be readily utilized to help a broader group of cancer patients.
Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic dark matter, or the portion of the human genome that is normally not expressed as protein. Dark Antigen-encoding sequences are usually silenced in healthy cells but are activated and presented on tumor cells. They are associated with specific cancer types and, importantly, are shared across patients. Since typically not visible to the immune system, they represent a large potential repertoire of novel antigens that can be developed as targets for new immunotherapies.
“We are extremely pleased to enter this strategic licensing agreement, our first major deal leveraging our pioneering Dark Antigen discovery and validation capabilities,” said Kevin Pojasek, President and CEO of Enara Bio. “Boehringer Ingelheim is an innovation-led company dedicated to producing breakthrough treatments with a significant focus on cancer. We are excited to build this relationship and are encouraged that Boehringer Ingelheim shares our view of the potential of Dark Antigens to be a source of important and unconventional targets for novel cancer immunotherapies. This agreement provides strong validation for our science and our approach to exploiting the cancer-associated antigenic repertoire derived from genomic dark matter and we look forward to a productive collaboration.”
This collaboration with Enara Bio is the latest of several strategic partnerships and acquisitions for Boehringer Ingelheim to build its cancer vaccine platform and provides important validation for Enara Bio’s Dark Antigen platform. The past acquisitions of ViraTherapeutics and AMAL Therapeutics’ vaccine modalities coupled with Enara Bio’s capabilities position Boehringer Ingelheim to develop sophisticated virus and vaccine modalities for its prime/boost vaccine platform.
Under the agreement, Boehringer Ingelheim has the option to license Dark Antigens discovered and validated by Enara Bio. Boehringer Ingelheim will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer immunotherapies, including therapeutic vaccines and T-cell redirecting biologics. Enara Bio retains rights to use any discovered antigens for use in cell therapy-based products.
Enara Bio is eligible to receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumor type that is explored. Enara Bio is also eligible to receive more than EUR 876 million in clinical, regulatory and commercial milestones, in addition to royalties on future product sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/strategic-collaboration-enarabio
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005444/en/
Contact information
Media Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: 49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: 203-791-6672
press@boehringer-ingelheim.com
Enara Bio
Enara Bio Limited
Kevin Pojasek, CEO
P: +44(0)1865 504 994
info@enarabio.com
Citigate Dewe Rogerson
Mark Swallow, Frazer Hall, Nathaniel Dahan
P: +44 (0)20 7638 9571
enarabio@citigatedewerogerson.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis and Ottawa Senators Renew Partnership, Uniting National Capital Region26.6.2025 21:32:00 EEST | Press release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is proud to announce a renewed three-year partnership with the Ottawa Senators and their AHL affiliate, the Belleville Senators. This collaboration is designed to amplify Kinaxis’ brand visibility, deepen community roots, and create unforgettable experiences for customers, prospects, and employees. As two proud Ottawa-based organizations, Kinaxis and the Senators will come together again to celebrate local talent, foster youth development, and drive meaningful community engagement. The partnership will also spotlight the Kinaxis brand across high-visibility platforms—including center ice at Canadian Tire Centre, LED rings, and digital dashboards during home and away games—ensuring a powerful presence throughout the NHL season. “At Kinaxis, we believe in the power of community and the importance of showing up where it matters most,” said Megan Paterson, chief operating officer at Kinaxis. “This partnership is
CB Insights Unveils Industry's First AI Agent Workforce for M&A, Partnerships, Competitive Intelligence, Deal Sourcing, GTM, and More26.6.2025 19:49:00 EEST | Press release
CB Insights, the leading provider of predictive market intelligence, today announced the launch of its Team of Agents – the industry's first comprehensive AI agent workforce designed specifically to enable business leaders with always-on market intelligence for strategic decision-making. CB Insights’ growing team of agents starts with 11 specialized agents that work continuously to uncover insights, translate proprietary data into action, and accelerate smart decisions by providing the external intelligence layer that enterprises need to compete effectively across business development, investments, partnerships, GTM, and competitive intelligence. While generic AI assistants struggle with business context and lack reliable external data, CB Insights' Team of Agents delivers validated intelligence and data science on over 10 million companies and 1,500 tech markets through purpose-built specialists that understand the nuanced requirements of strategic business functions. Enterprise clien
Pure Lithium and CEO Emilie Bodoin Recognized for Innovations at Reuters Global Energy Transition Awards26.6.2025 19:27:00 EEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that it has won the 2025 Reuters Global Energy Transition award for R&D Achievement. The award, presented at a June 24th ceremony in New York, recognizes research and development projects that promote a science-oriented energy transition while yielding promising potential and achievement. Pure Lithium has developed lithium metal batteries with double the energy density of lithium-ion cells and an industry-leading cycle life. By prioritizing research and development, the company achieved step-change advancements in battery technology and has built a strong portfolio of 119 patents and applications. “We’re thrilled to be selected for this prestigious award, which recognizes the hard work, dedication and creativity of our world-class team,” said Pure Lithium Founder and CEO Emilie Bodoin. “We know that commercializing a new chemistry requires a delicate balance of
Ant Group Launches AI Healthcare App AQ Amid Push into Healthcare Sector26.6.2025 17:41:00 EEST | Press release
Ant Group today launched its AI healthcare app, AQ, to accelerate the company’s entry into the healthcare sector. The app helps users manage their daily healthcare needs with over 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized medical advice. It also connects users to digital services from over 5,000 hospitals and nearly 1 million doctors across China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626728870/en/ Ant Group launched the AI healthcare app AQ to accelerate its entry into the healthcare sector By around 2035, over 400 million people, or more than 30% of China’s population, will be aged 60 or older, according to projections from China’s National Health Commission. This demographic shift is expected to significantly increase healthcare demand in the country. “Ant Group hopes that through AQ, it can provide everyone with a trusted healthcare manager, advancing
Wasabi Technologies Becomes Official Cloud Storage Partner and Front-of-Jersey Sponsor of USA Rugby26.6.2025 17:00:00 EEST | Press release
Wasabi Technologies, the hot cloud storage company, today announced it has strengthened its sports sponsorship program as the Official Cloud Storage Partner of USA Rugby. This milestone partnership unites two organizations committed to rapid growth, excellence, and technology innovation. Wasabi is purpose-built for media-rich industries like sports and entertainment and offers simple, fast, and predictable cloud storage for organizations with growing content archives. USA Rugby now stands alongside Wasabi’s compelling sponsorship portfolio of teams unlocking the power of their data, including iconic organizations, like the Boston Red Sox and Liverpool Football Club. “With digital transformation being top of mind for all sports organizations, we can’t think of a better partner than Wasabi to innovate alongside,” said USA Rugby CEO, Bill Goren. “Wasabi has established itself as a true industry leader, and we are eager to work with them to mutually drive growth both on and off the rugby p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom